Back
1 October 2026
The ITA reports that baseball player Daniel Yonemura has agreed¹ to the consequences for his anti-doping rule violation (ADRV).
The player provided a sample collected by the ITA during a in-competiton doping control performed on 4 March 2025 during the World Baseball Classic Qualifiers, which yielded an adverse analytical finding² (AAF) for Anastrozole. Anastrozole is listed under class S4. Hormone and Metabolic Modulators according to the prohibited list of the World Anti-Doping Agency (WADA). It is prohibited at all times (in- and out-of-competition) and is classified as a specified substance. Anastrozole can be used by athletes to manipulate the body’s natural hormone balance to enhance performance and manage the side effects of other performance-enhancing drugs.
The athlete did not challenge the ADRV and agreed with the consequences proposed by the ITA. Accordingly, the case was resolved via and acceptance of consequences.
The athlete’s period of ineligibility is from 1 November 2025 until 31 October 2027. In addition, all the athlete’s competitive results as from 4 March 2025 are disqualified.
The decision may be challenged before the appeal division of the Court of Arbitration of Sport by the parties with a right of appeal in accordance with Article 13.2.3 of the WBSC anti-doping rules.
¹ Athletes have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the athlete’s case file and establish the applicable consequences pursuant to the anti-doping rules and the athlete will have the right to accept the proposed consequences. If the athlete refuses the proposed consequences, the case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.1.3. of the WBSC anti-doping rules and 8.3 of the World Anti-Doping Code and is commonly referred to as an agreement on consequences and is deemed a WBSC/ITA decision.
² A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a sample the presence of a prohibited substance or its metabolites or markers or evidence of the use of a prohibited method.
